Pawel Kalinski - Publications

University of Pittsburgh, Pittsburgh, PA, United States 
Immunology, Cell Biology

47 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Sonmez UM, Wood A, Justus K, Jiang W, Syed-Picard F, LeDuc PR, Kalinski P, Davidson LA. Chemotactic Responses of Jurkat Cells in Microfluidic Flow-Free Gradient Chambers. Micromachines. 11. PMID 32260431 DOI: 10.3390/mi11040384  0.4
2018 Theodoraki MN, Yerneni S, Sarkar SN, Orr B, Muthuswamy R, Voyten J, Modugno F, Jiang W, Grimm M, Basse PH, Bartlett DL, Edwards R, Kalinski P. Helicase-driven activation of NFκB-COX2 mediates the immunosuppressive component of dsRNA-driven inflammation in the human tumor microenvironment. Cancer Research. PMID 29853604 DOI: 10.1158/0008-5472.CAN-17-3985  0.6
2018 Obermajer N, Urban J, Wieckowski E, Muthuswamy R, Ravindranathan R, Bartlett DL, Kalinski P. Promoting the accumulation of tumor-specific T cells in tumor tissues by dendritic cell vaccines and chemokine-modulating agents. Nature Protocols. 13: 335-357. PMID 29345636 DOI: 10.1038/nprot.2017.130  0.6
2017 Muthuswamy R, Okada NJ, Jenkins FJ, McGuire K, McAuliffe PF, Zeh HJ, Bartlett DL, Wallace C, Watkins S, Henning JD, Bovbjerg DH, Kalinski P. Epinephrine Promotes COX-2-dependent Immune Suppression in Myeloid Cells and Cancer Tissues. Brain, Behavior, and Immunity. PMID 28212885 DOI: 10.1016/j.bbi.2017.02.008  0.6
2016 Muthuswamy R, Corman JM, Dahl K, Chatta GS, Kalinski P. Functional reprogramming of human prostate cancer to promote local attraction of effector CD8(+) T cells. The Prostate. PMID 27199259 DOI: 10.1002/pros.23194  0.6
2016 Francis L, Guo ZS, Liu Z, Ravindranathan R, Urban JA, Sathaiah M, Magge D, Kalinski P, Bartlett DL. Modulation of chemokines in the tumor microenvironment enhances oncolytic virotherapy for colorectal cancer. Oncotarget. PMID 26956047 DOI: 10.18632/oncotarget.7907  0.36
2015 Muthuswamy R, Wang L, Pitteroff J, Gingrich JR, Kalinski P. Combination of IFNα and poly-I:C reprograms bladder cancer microenvironment for enhanced CTL attraction. Journal For Immunotherapy of Cancer. 3: 6. PMID 25806105 DOI: 10.1186/s40425-015-0050-8  0.6
2015 Zaccard CR, Watkins SC, Kalinski P, Fecek RJ, Yates AL, Salter RD, Ayyavoo V, Rinaldo CR, Mailliard RB. CD40L induces functional tunneling nanotube networks exclusively in dendritic cells programmed by mediators of type 1 immunity. Journal of Immunology (Baltimore, Md. : 1950). 194: 1047-56. PMID 25548234 DOI: 10.4049/jimmunol.1401832  0.36
2015 Zaccard CR, Watkins SC, Kalinski P, Fecek RJ, Yates AL, Salter RD, Ayyavoo V, Rinaldo CR, Mailliard RB. CD40L induces functional tunneling nanotube networks exclusively in dendritic cells programmed by mediators of type 1 immunity Journal of Immunology. 194: 1047-1056. DOI: 10.4049/jimmunol.1401832  0.36
2014 Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, ... ... Kalinski P, et al. Classification of current anticancer immunotherapies. Oncotarget. 5: 12472-508. PMID 25537519 DOI: 10.18632/oncotarget.2998  0.36
2013 Wong JL, Muthuswamy R, Bartlett DL, Kalinski P. IL-18-based combinatorial adjuvants promote the intranodal production of CCL19 by NK cells and dendritic cells of cancer patients. Oncoimmunology. 2: e26245. PMID 24228233 DOI: 10.4161/onci.26245  0.6
2013 Wong JL, Berk E, Edwards RP, Kalinski P. IL-18-primed helper NK cells collaborate with dendritic cells to promote recruitment of effector CD8+ T cells to the tumor microenvironment. Cancer Research. 73: 4653-62. PMID 23761327 DOI: 10.1158/0008-5472.CAN-12-4366  1
2013 Kalinski P, Muthuswamy R, Urban J. Dendritic cells in cancer immunotherapy: vaccines and combination immunotherapies. Expert Review of Vaccines. 12: 285-95. PMID 23496668 DOI: 10.1586/erv.13.22  0.6
2013 Vernon PJ, Loux TJ, Schapiro NE, Kang R, Muthuswamy R, Kalinski P, Tang D, Lotze MT, Zeh HJ. The receptor for advanced glycation end products promotes pancreatic carcinogenesis and accumulation of myeloid-derived suppressor cells. Journal of Immunology (Baltimore, Md. : 1950). 190: 1372-9. PMID 23269246 DOI: 10.4049/jimmunol.1201151  0.6
2012 Berk E, Kalinski P. Lymphocyte-polarized DC1s: Effective inducers of tumor-specific CTLs. Oncoimmunology. 1: 1443-1444. PMID 23243623 DOI: 10.4161/onci.21295  1
2012 Tarhini AA, Butterfield LH, Shuai Y, Gooding WE, Kalinski P, Kirkwood JM. Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-α or TLR-9 agonist and GM-CSF with peptide vaccination. Journal of Immunotherapy (Hagerstown, Md. : 1997). 35: 702-10. PMID 23090079 DOI: 10.1097/CJI.0b013e318272569b  0.36
2012 Muthuswamy R, Berk E, Junecko BF, Zeh HJ, Zureikat AH, Normolle D, Luong TM, Reinhart TA, Bartlett DL, Kalinski P. NF-κB hyperactivation in tumor tissues allows tumor-selective reprogramming of the chemokine microenvironment to enhance the recruitment of cytolytic T effector cells. Cancer Research. 72: 3735-43. PMID 22593190 DOI: 10.1158/0008-5472.CAN-11-4136  1
2012 Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P, Ferrone S. Immunotherapy of cancer in 2012. Ca: a Cancer Journal For Clinicians. 62: 309-35. PMID 22576456 DOI: 10.3322/caac.20132  0.36
2012 Berk E, Muthuswamy R, Kalinski P. Lymphocyte-polarized dendritic cells are highly effective in inducing tumor-specific CTLs. Vaccine. 30: 6216-24. PMID 22561311 DOI: 10.1016/j.vaccine.2012.04.077  1
2012 Umemura N, Zhu J, Mburu YK, Forero A, Hsieh PN, Muthuswamy R, Kalinski P, Ferris RL, Sarkar SN. Defective NF-κB signaling in metastatic head and neck cancer cells leads to enhanced apoptosis by double-stranded RNA. Cancer Research. 72: 45-55. PMID 22058147 DOI: 10.1158/0008-5472.CAN-11-1484  0.6
2011 Obermajer N, Muthuswamy R, Odunsi K, Edwards RP, Kalinski P. PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Research. 71: 7463-70. PMID 22025564 DOI: 10.1158/0008-5472.CAN-11-2449  0.6
2011 Obermajer N, Muthuswamy R, Lesnock J, Edwards RP, Kalinski P. Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood. 118: 5498-505. PMID 21972293 DOI: 10.1182/blood-2011-07-365825  0.6
2011 Kalinski P, Edington H, Zeh HJ, Okada H, Butterfield LH, Kirkwood JM, Bartlett DL. Dendritic cells in cancer immunotherapy: vaccines or autologous transplants? Immunologic Research. 50: 235-47. PMID 21717071 DOI: 10.1007/s12026-011-8224-z  0.36
2011 Wong JL, Mailliard RB, Moschos SJ, Edington H, Lotze MT, Kirkwood JM, Kalinski P. Helper activity of natural killer cells during the dendritic cell-mediated induction of melanoma-specific cytotoxic T cells. Journal of Immunotherapy (Hagerstown, Md. : 1997). 34: 270-8. PMID 21389871 DOI: 10.1097/CJI.0b013e31820b370b  0.36
2011 Zhao X, Bose A, Komita H, Taylor JL, Kawabe M, Chi N, Spokas L, Lowe DB, Goldbach C, Alber S, Watkins SC, Butterfield LH, Kalinski P, Kirkwood JM, Storkus WJ. Intratumoral IL-12 gene therapy results in the crosspriming of Tc1 cells reactive against tumor-associated stromal antigens. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 805-14. PMID 21189473 DOI: 10.1038/mt.2010.295  0.36
2010 Muthuswamy R, Mueller-Berghaus J, Haberkorn U, Reinhart TA, Schadendorf D, Kalinski P. PGE(2) transiently enhances DC expression of CCR7 but inhibits the ability of DCs to produce CCL19 and attract naive T cells. Blood. 116: 1454-9. PMID 20498301 DOI: 10.1182/blood-2009-12-258038  0.6
2010 Helfer BM, Balducci A, Nelson AD, Janjic JM, Gil RR, Kalinski P, de Vries IJ, Ahrens ET, Mailliard RB. Functional assessment of human dendritic cells labeled for in vivo (19)F magnetic resonance imaging cell tracking. Cytotherapy. 12: 238-50. PMID 20053146 DOI: 10.3109/14653240903446902  0.36
2010 Watchmaker PB, Berk E, Muthuswamy R, Mailliard RB, Urban JA, Kirkwood JM, Kalinski P. Independent regulation of chemokine responsiveness and cytolytic function versus CD8+ T cell expansion by dendritic cells. Journal of Immunology (Baltimore, Md. : 1950). 184: 591-7. PMID 20018619 DOI: 10.4049/jimmunol.0902062  1
2010 Kalinski P, Wieckowski E, Muthuswamy R, de Jong E. Generation of stable Th1/CTL-, Th2-, and Th17-inducing human dendritic cells. Methods in Molecular Biology (Clifton, N.J.). 595: 117-33. PMID 19941108 DOI: 10.1007/978-1-60761-421-0_7  0.6
2009 Sasaki K, Pardee AD, Qu Y, Zhao X, Ueda R, Kohanbash G, Bailey LM, Okada H, Muthuswamy R, Kalinski P, Basse PH, Falo LD, Storkus WJ. IL-4 suppresses very late antigen-4 expression which is required for therapeutic Th1 T-cell trafficking into tumors. Journal of Immunotherapy (Hagerstown, Md. : 1997). 32: 793-802. PMID 19752754 DOI: 10.1097/CJI.0b013e3181acec1e  0.6
2009 Kalinski P, Urban J, Narang R, Berk E, Wieckowski E, Muthuswamy R. Dendritic cell-based therapeutic cancer vaccines: What we have and what we need Future Oncology. 5: 379-390. PMID 19374544 DOI: 10.2217/fon.09.6  1
2009 Fujita M, Zhu X, Ueda R, Sasaki K, Kohanbash G, Kastenhuber ER, McDonald HA, Gibson GA, Watkins SC, Muthuswamy R, Kalinski P, Okada H. Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells--significant roles of CXCL10. Cancer Research. 69: 1587-95. PMID 19190335 DOI: 10.1158/0008-5472.CAN-08-2915  0.6
2009 Giermasz AS, Urban JA, Nakamura Y, Watchmaker P, Cumberland RL, Gooding W, Kalinski P. Type-1 polarized dendritic cells primed for high IL-12 production show enhanced activity as cancer vaccines. Cancer Immunology, Immunotherapy : Cii. 58: 1329-36. PMID 19156413 DOI: 10.1007/s00262-008-0648-5  0.36
2008 Muthuswamy R, Urban J, Lee JJ, Reinhart TA, Bartlett D, Kalinski P. Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation. Cancer Research. 68: 5972-8. PMID 18632653 DOI: 10.1158/0008-5472.CAN-07-6818  0.6
2008 Lee JJ, Foon KA, Mailliard RB, Muthuswamy R, Kalinski P. Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia. Journal of Leukocyte Biology. 84: 319-25. PMID 18426971 DOI: 10.1189/jlb.1107737  0.6
2008 Watchmaker PB, Urban JA, Berk E, Nakamura Y, Mailliard RB, Watkins SC, van Ham SM, Kalinski P. Memory CD8+ T cells protect dendritic cells from CTL killing. Journal of Immunology (Baltimore, Md. : 1950). 180: 3857-65. PMID 18322193  1
2007 Nakamura Y, Watchmaker P, Urban J, Sheridan B, Giermasz A, Nishimura F, Sasaki K, Cumberland R, Muthuswamy R, Mailliard RB, Larregina AT, Falo LD, Gooding W, Storkus WJ, Okada H, ... ... Kalinski P, et al. Helper function of memory CD8+ T cells: heterologous CD8+ T cells support the induction of therapeutic cancer immunity. Cancer Research. 67: 10012-8. PMID 17942935 DOI: 10.1158/0008-5472.CAN-07-1735  0.6
2007 Wesa A, Kalinski P, Kirkwood JM, Tatsumi T, Storkus WJ. Polarized type-1 dendritic cells (DC1) producing high levels of IL-12 family members rescue patient TH1-type antimelanoma CD4+ T cell responses in vitro. Journal of Immunotherapy (Hagerstown, Md. : 1997). 30: 75-82. PMID 17198085 DOI: 10.1097/01.cji.0000211316.15278.6e  0.36
2007 Ito N, DeMarco RA, Mailliard RB, Han J, Rabinowich H, Kalinski P, Stolz DB, Zeh HJ, Lotze MT. Cytolytic cells induce HMGB1 release from melanoma cell lines. Journal of Leukocyte Biology. 81: 75-83. PMID 16968820 DOI: 10.1189/jlb.0306169  0.36
2006 Kalinski P, Nakamura Y, Watchmaker P, Giermasz A, Muthuswamy R, Mailliard RB. Helper roles of NK and CD8+ T cells in the induction of tumor immunity. Polarized dendritic cells as cancer vaccines. Immunologic Research. 36: 137-46. PMID 17337774 DOI: 10.1385/IR:36:1:137  0.6
2005 Mailliard RB, Alber SM, Shen H, Watkins SC, Kirkwood JM, Herberman RB, Kalinski P. IL-18-induced CD83+CCR7+ NK helper cells. The Journal of Experimental Medicine. 202: 941-53. PMID 16203865 DOI: 10.1084/jem.20050128  0.36
2005 Kalinski P, Mailliard RB, Giermasz A, Zeh HJ, Basse P, Bartlett DL, Kirkwood JM, Lotze MT, Herberman RB. Natural killer-dendritic cell cross-talk in cancer immunotherapy. Expert Opinion On Biological Therapy. 5: 1303-15. PMID 16197336 DOI: 10.1517/14712598.5.10.1303  0.36
2005 Kalinski P, Giermasz A, Nakamura Y, Basse P, Storkus WJ, Kirkwood JM, Mailliard RB. Helper role of NK cells during the induction of anticancer responses by dendritic cells. Molecular Immunology. 42: 535-9. PMID 15607810 DOI: 10.1016/j.molimm.2004.07.038  0.36
2004 Mailliard RB, Wankowicz-Kalinska A, Cai Q, Wesa A, Hilkens CM, Kapsenberg ML, Kirkwood JM, Storkus WJ, Kalinski P. alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Research. 64: 5934-7. PMID 15342370 DOI: 10.1158/0008-5472.CAN-04-1261  0.36
2003 Mailliard RB, Son YI, Redlinger R, Coates PT, Giermasz A, Morel PA, Storkus WJ, Kalinski P. Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function. Journal of Immunology (Baltimore, Md. : 1950). 171: 2366-73. PMID 12928383 DOI: 10.4049/jimmunol.171.5.2366  0.36
2002 Lokshin AE, Kalinski P, Sassi RR, Mailliard RB, Müller-Berghaus J, Storkus WJ, Peng X, Marrangoni AM, Edwards RP, Gorelik E. Differential regulation of maturation and apoptosis of human monocyte-derived dendritic cells mediated by MHC class II. International Immunology. 14: 1027-37. PMID 12202400  0.36
2002 Mailliard RB, Egawa S, Cai Q, Kalinska A, Bykovskaya SN, Lotze MT, Kapsenberg ML, Storkus WJ, Kalinski P. Complementary dendritic cell-activating function of CD8+ and CD4+ T cells: helper role of CD8+ T cells in the development of T helper type 1 responses. The Journal of Experimental Medicine. 195: 473-83. PMID 11854360 DOI: 10.1084/jem.20011662  0.36
Show low-probability matches.